Increased paediatric hospitalizations for empyema in Australia after introduction of the 7-valent pneumococcal conjugate vaccine
Roxanne E Strachan a, Thomas L Snelling b & Adam Jaffé c
a. Department of Respiratory Medicine, Sydney Children’s Hospital, High Street, Randwick, Sydney NSW 2031, Australia.
b. Department of Immunology and Infectious Diseases, Sydney Children’s Hospital, Sydney, Australia.
c. School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia.
Correspondence to Roxanne E Strachan (e-mail: firstname.lastname@example.org).
(Submitted: 27 June 2012 – Revised version received: 23 October 2012 – Accepted: 30 October 2012 – Published online: 11 December 2012.)
Bulletin of the World Health Organization 2013;91:167-173. doi: 10.2471/BLT.12.109231
Streptococcus pneumoniae is the leading cause of bacterial infection in children worldwide and the most common cause of bacterial pneumonia in Australia, where it accounts for approximately one third of all cases.1 In Australia, about 0.7% of all cases of pneumonia in children are complicated by empyema, which requires hospitalization for treatment and possible drainage.2 S. pneumoniae is also the most common pathogen causing empyema.3 The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in Australia's national immunization programme in two phases: in 2001 for indigenous and immunocompromised children less than 2 years of age, and in January 2005 for all children in this age group. In July 2011 the PCV7 was replaced by a 13-valent conjugate vaccine. The PCV7 was administered as a three-dose series at ages 2, 4 and 6 months, without a booster.
Although pneumococcal conjugate vaccines have reduced invasive pneumococcal disease rates in children and adults throughout the world, 4–9 several studies have reported a concomitant increase in empyema cases, both in the vaccinated and the non-vaccinated population.10–17 Because up to 90% of these cases have been caused by bacterial serotypes not included in the PCV7,10–12 some fear that empyema may have emerged as a “replacement disease”, i.e. disease produced by non-vaccine-related serotypes that have become predominant. Although we have reported the rates of childhood empyema in Australia elsewhere,2 no previous studies have examined how the introduction of PCV7 has affected childhood empyema rates in this country. The objective of this study is to examine the incidence of paediatric hospitalizations for pneumonia and empyema in Australia before and after the introduction of the PCV7.
We reviewed the annual incidence in Australia of paediatric hospitalizations for empyema and pneumonia (viral and bacterial) before and after the introduction of PCV7 among children in the following age groups: < 1 year, 1–4 years, 5–9 years, 10–14 years and 15–19 years. The pre-vaccine period extended from July 1998 to June 2004; the post-vaccine period, from July 2005 to June 2010. We excluded all hospitalizations from July 2004 to June 2005 because the PCV7 was introduced midway through this period. In Australia, hospital discharges are coded for the principal diagnosis (primary cause) in accordance with the coding system of the International Classification of Diseases, tenth revision. The Australian Institute of Health and Welfare collated the national hospital discharge codes supplied by state and territory authorities per financial year, from July to June, and introduced them into the National Hospital Morbidity Database, which is publicly available. From this database we obtained data on the hospitalizations in the age groups already indicated. Although a “child” is generally defined as a person under the age of 18 years, data cubes were only available for these age groups. We included codes for bacterial pneumonia (J13–J15.9, J16.8, J18.0, J18.1, J18.8–J20.0) and viral pneumonia (J10.0, J11.0, J12.0–J12.2, J12.8, J12.9), as well as codes for empyema (J86–J86.9). We expressed hospitalization incidence as hospitalizations per 106 person–years and used census data for the population less than 20 years of age from the Australian Bureau of Statistics to calculate the number of person–years in each study period. There were 31 846 901 and 27 713 068 person–years in the pre- and post-vaccine periods, respectively.
We compared the incidence of hospitalization for all pneumonias, as well as for bacterial and viral pneumonia separately and for empyema, in the pre- and post-vaccine periods. We estimated the expected number of hospitalizations in the post-vaccine period by multiplying the hospitalization incidence rate in the pre-vaccine period by the number of person–years in the post-vaccine period. We also calculated incidence rate differences (IRD = incidence rate in pre-vaccine period minus incidence rate in post-vaccine period) and incidence rate ratios (IRR = incidence rate in post-vaccine period divided by incidence rate in pre-vaccine period) with their exact 95% confidence intervals (CIs), assuming a Poisson distribution.
Overall, 78 552 and 53 052 pneumonia-coded hospitalizations took place in the periods before and after the introduction of the PCV7, respectively. The incidence of hospitalizations was 22% lower in the post-vaccine period than in the pre-vaccine period (IRR: 0.78; 95% CI: 0.77–0.78) (Fig. 1, Table 1). This reduction in hospitalization incidence was greatest among children whose age made them eligible for vaccination (i.e. < 1 year and 1 to 4 years in age) but was observed in all age groups. Most of the decrease in the incidence of hospitalizations was noted among children hospitalized for pneumonia with a bacteria-specific code (Table 1). In contrast, the incidence of hospitalizations coded as being for empyema was 35% higher (IRR: 1.35; 95% CI: 1.14–1.59) in the post-vaccine period than in the pre-vaccine period (Fig. 2, Table 1); the incidence of hospitalizations coded for viral pneumonia was 31% higher (IRR: 1.31; 95% CI: 1.27–1.35) (Table 1). However, the absolute increase in the incidence of hospitalizations for empyema and for viral pneumonia (3 and 70 hospitalizations more per 106 person–years, respectively) was much smaller than the absolute decrease in the incidence of hospitalization for bacterial pneumonia (623 hospitalizations fewer per 106 person–years). On subgroup analysis, the increase in empyema was only significant among children aged 1 to 4 years, which was the age group with the largest number of hospitalizations. There was little evidence of an increase in empyema among children born before the PCV7 became routinely available in Australia (i.e. those aged 5–9, 10–14 and 15–19 years).
Fig. 1. Incidencea of hospital admissions for pneumonia, Australia, 1998–2004 and 2005–2010
Table 1. Incidence rate differences (IRDs) and incidence rate ratios (IRRs) for paediatric hospitalizations for pneumonia and empyema before and after the introduction of the 7-valent pneumococcal conjugate vaccine, Australia
Fig. 2. Incidencea of hospital admissions for empyema, Australia, 1998–2004 and 2005–2010
Hospitalizations for childhood empyema in Australia appear to have increased after the introduction of the PCV7, despite a significant decrease in hospitalizations for pneumonia as a whole over the same period. The reduction in the incidence of hospitalizations for pneumonia was greatest among children whose age made them eligible for vaccination (i.e. < 1 year and 1–4 years in age), but more modest reductions were also observed among older children. Although the increase in the incidence of hospitalizations for empyema (which is present in fewer than 1% of pneumonia hospitalizations) was greatly outweighed by the reduction in the incidence of hospitalizations for pneumonia, empyema accounts for an important fraction of the cases of severe, complicated pneumonia. We assume that the IRDs we report here are primarily the result of vaccine-attributable changes in the epidemiology of childhood pneumonia in Australia, although they could also be reflecting other factors, including underlying secular trends. Our method is analogous to the method used in studies in England and Scotland on trends in childhood pneumonia and empyema.18,19
We based this analysis on publicly available hospitalization and population data. A limitation of the study is that we used hospital discharge data coded for the primary diagnosis. Bacterial pneumonias in children are difficult to distinguish from viral pneumonias because bacterial culture has a low positive yield. Furthermore, as many as 33% of the children with pneumonia are infected by mixed pathogens.20 Hence, the coding data may be inaccurate. To avoid this problem, we chose to compare the hospitalization rates for pneumonia as a whole rather than for bacteria-specific pneumonias. The reduction in hospitalizations for bacterial pneumonia was accompanied by a smaller absolute increase in pneumonias coded as viral (Table 1). This might reflect changes in coding practices or perhaps improvements in molecular diagnostics and a greater availability of viral antigens over time. Pneumonias coded as viral decreased among infants. This was also seen in a field trial of conjugate vaccine that demonstrated a reduction in viral pneumonia, presumably because viral pneumonia in young children is often complicated by co-infection with pneumococcus.21
Another limitation of our study is that we only included hospitalizations for which pneumonia and empyema were the primary diagnosis. Hence, our findings probably represent minimum estimates of disease incidence. Furthermore, we were unable to perform subgroup analysis by ethnic group and place of residence because these data are not publicly available.
For convenience, we examined the period preceding and the period following the introduction of the PCV7. Since the vaccine was introduced in January 2005, we excluded from the analysis all data for the period from July 2004 to June 2005 (Table 1). Nonetheless, the post-vaccine period included some children whose age would not have made them eligible for vaccination, and this could have resulted in an underestimation of the vaccine’s effect except in the youngest age group (< 1 year). In addition, targeted vaccination of indigenous children occurred during part of the pre-vaccine period. However, this probably affected our estimates only minimally since indigenous people account for only 3% of the Australian population.22
Although the PCV7 has substantially reduced the rates of invasive pneumococcal disease, reports from around the world suggest that the incidence of empyema in children has increased following the introduction of the PCV7.10,11 The reasons for this are not entirely clear, but virulent serotypes not covered by the PCV7 may have emerged as a result of the selective pressure applied by the vaccine. Most cases of empyema among Australian children are caused by serotypes 1, 3 and 19A,23 which are believed to be particularly virulent and more likely to invade the pleural cavity.24,25 The reported increase in serotypes 1, 3 and 19A among invasive isolates might explain the increase in empyema but not in pneumonia per se.10–12 On the other hand, an increase in the incidence of empyema was observed in some studies before the introduction of the PCV7.2,26–28 This suggests that the observed association between the introduction of the PCV7 and the rise in empyema incidence may be coincidental.
Irrespective of its cause, the observed increase in empyema adds to health system costs. In a clinical study in the United Kingdom of Great Britain and Northern Ireland, we calculated that the cost per admission for a child with empyema was between 7600 and 11 700 United States dollars (US$).29 A study in the United States yielded similar estimates.30 Thus, the 35% increase in empyema admissions observed in Australia following the introduction of the PCV7 has brought an additional expenditure of US$ 126 160–194 220 per year to the Australian health-care system. On the other hand, the reduction in pneumonia admissions has saved the health system US$ 3.8 million–6.1 million annually (based on United Kingdom cost-analysis data for pneumonia admissions).31 Although modest, the additional costs owing to the increase in cases of empyema among children would be reduced by the use of a vaccine with broader pneumococcal serotype coverage.3
In July 2011 (October 2011 in Australia’s Northern Territory), Australia’s 13-valent pneumococcal conjugate vaccine was introduced into the national immunization programme. This vaccine includes six serotypes that the PCV7 does not contain, including serotypes 1, 3 and 19A. Despite this, the large number of pneumococcal serotypes that have been identified makes it likely that other virulent pneumococcal strains will emerge. This underscores the need for on-going, enhanced molecular surveillance of invasive pneumococcal strains, including those that cause empyema in children. The results of such surveillance, which is already being practised in the United Kingdom, will directly affect future policy decisions regarding the adoption of newer vaccines as part of the national immunization schedule in Australia.
AJ previously received an unrestricted grant from GlaxoSmithKline, Belgium.
- Burgner D, Richmond P. The burden of pneumonia in children: an Australian perspective. Paediatr Respir Rev 2005; 6: 94-100 pmid: 15911454.
- Strachan R, Jaffé A, Australian Research Network in Empyema. Assessment of the burden of paediatric empyema in Australia. J Paediatr Child Health 2009; 45: 431-6 doi: 10.1111/j.1440-1754.2009.01533.x pmid: 19722296.
- Strachan RE, Cornelius A, Gilbert GL, Gulliver T, Martin A, McDonald T, et al., Australian Research Network in Empyema, et al. Bacterial causes of empyema in children, Australia, 2007–2009. Emerg Infect Dis 2011; 17: 1839-45 doi: 10.3201/eid1710.101825 pmid: 22000353.
- Whitney CG, Farley MM, Hadler JL, Harrison LH, Bennett NM, Lynfield R, et al., Active Bacterial Core Surveillance of the Emerging Infections Program Network, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46 doi: 10.1056/NEJMoa022823 pmid: 12724479.
- Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction – eight states, 1998–2005. MMWR Morb Mortal Wkly Rep 2008; 57: 144-8 pmid: 18272956.
- Chapman KE, Wilson D, Gorton R. Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England. Epidemiol Infect 2012; 5: 1-9 doi: 10.1017/S0950268812000763 pmid: 22564258.
- Johnson DR, D’Onise K, Holland RA, Raupach JC, Koehler AP. Pneumococcal disease in South Australia: vaccine success but no time for complacency. Vaccine 2012; 30: 2206-11 doi: 10.1016/j.vaccine.2011.12.119 pmid: 22273663.
- Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009; 49: 205-12 doi: 10.1086/599827 pmid: 19508165.
- Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, et al., et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis 2008; 47: 476-84 doi: 10.1086/590001 pmid: 18627249.
- Calbo E, Díaz A, Cañadell E, Fábrega J, Uriz S, Xercavins M, et al., Spanish Pneumococcal Infection Study Network, et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect 2006; 12: 867-72 doi: 10.1111/j.1469-0691.2006.1502_1.x pmid: 16882291.
- Hendrickson DJ, Blumberg DA, Joad JP, Jhawar S, McDonald RJ. Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2008; 27: 1030-2 doi: 10.1097/INF.0b013e31817e5188 pmid: 18845981.
- Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J 2006; 25: 250-4 doi: 10.1097/01.inf.0000202137.37642.ab pmid: 16511389.
- Bekri H, Cohen R, Varon E, Madhi F, Gire R, Guillot F, et al., et al. Streptococcus pneumoniae serotypes involved in children with pleural empyemas in France. Arch Pediatr 2007; 14: 239-43 pmid: 17276044.
- Byington CL, Spencer LY, Johnson TA, Pavia AT, Allen D, Mason EO, et al., et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: Risk factors and microbiological associations. Clin Infect Dis 2002; 34: 434-40 pmid: 11797168.
- Calbo E, Garau J. Invasive pneumococcal disease in children: changing serotypes and clinical expression of disease. Clin Infect Dis 2005; 41: 1821-2 pmid: 16288412.
- Obando I, Arroyo LA, Sanchez-Tatay D, Moreno D, Hausdorff WP, Brueggemann AB. Molecular typing of pneumococci causing parapneumonic empyema in Spanish children using multilocus sequence typing directly on pleural fluid samples. Pediatr Infect Dis J 2006; 25: 962-3 pmid: 17006306.
- Obando I, Arroyo LA, Sanchez-Tatay D, Tarrago D, Moreno D, Hausdorff WP, et al., et al. Molecular epidemiology of paediatric invasive pneumococcal disease in southern Spain after the introduction of heptavalent pneumococcal conjugate vaccine. Clin Microbiol Infect 2007; 13: 347-8 pmid: 17391398.
- Roxburgh CS, Youngson GG, Townend JA, Turner SW. Trends in pneumonia and empyema in Scottish children in the past 25 years. Arch Dis Child 2008; 93: 316-8 doi: 10.1136/adc.2007.126540 pmid: 18006562.
- Koshy E, Murray J, Bottle A, Sharland M, Saxena S. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997–2008. Thorax 2010; 65: 770-4 doi: 10.1136/thx.2010.137802 pmid: 20805169.
- Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al., British Thoracic Society Standards of Care Committee, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66: ii1-23 doi: 10.1136/thoraxjnl-2011-200598 pmid: 21903691.
- Madhi SA, Klugman KP, Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10: 811-3 doi: 10.1038/nm1077 pmid: 15247911.
- Australian Bureau of Statistics [Internet]. Aboriginal and Torres Strait Islander population estimates, 2011 – preliminary. Camberra: ABS; 2012. Available from: http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/3101.0Feature%20Article1Mar%202012?opendocument&tabname=Summary&prodno=3101.0&issue=Mar%202012&num=&view= [accessed 10 December 2012].
- Strachan RE, Cornelius A, Gilbert GL, Gulliver T, Martin A, McDonald T, et al., et al. Pleural fluid nucleic acid testing enhances pneumococcal surveillance in children. Respirology 2012; 17: 114-9 doi: 10.1111/j.1440-1843.2011.02035.x pmid: 21848709.
- Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005; 5: 83-93 pmid: 15680778.
- Luján M, Gallego M, Belmonte Y, Fontanals D, Vallès J, Lisboa T, et al., et al. Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J 2010; 36: 1073-9 doi: 10.1183/09031936.00176309 pmid: 20150202.
- Eastham KM, Freeman R, Kearns AM, Eltringham G, Clark J, Leeming J, et al., et al. Clinical features, aetiology and outcome of empyema in children in the north east of England. Thorax 2004; 59: 522-5 doi: 10.1136/thx.2003.016105 pmid: 15170039.
- Playfor SD, Smyth AR, Stewart RJ. Increase in incidence of childhood empyema. Thorax 1997; 52: 932- pmid: 9404386.
- Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297: 1784-92 doi: 10.1001/jama.297.16.1784 pmid: 17456820.
- Sonnappa S, Cohen G, Owens CM, van Doorn C, Cairns J, Stanojevic S, et al., et al. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med 2006; 174: 221-7 doi: 10.1164/rccm.200601-027OC pmid: 16675783.
- St Peter SD, Tsao K, Harrison C, Jackson MA, Spilde TL, Keckler SJ, et al., et al. Thoracoscopic decortication vs tube thoracostomy with fibrinolysis for empyema in children: a prospective, randomized trial. J Pediatr Surg 2009; 44: 106-11discussion 111 doi: 10.1016/j.jpedsurg.2008.10.018 pmid: 19159726.
- Lorgelly PK, Atkinson M, Lakhanpaul M, Smyth AR, Vyas H, Weston V, et al., et al. Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis. Eur Respir J 2010; 35: 858-64 doi: 10.1183/09031936.00087209 pmid: 19717479.